Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-475P (RNA, U6 small nuclear 475, pseudogene) is a *pseudogene* member of the U6 small nuclear RNA (snRNA) family[1]. Functional U6 snRNAs are integral to the spliceosome complex, participating directly in pre-mRNA splicing and catalysis[5]. However, pseudogenes like RNU6-475P are believed not to be expressed or processed into functional RNA, and most are presumed to have no biological activity or impact on human disease[1][4]. Pseudogenes originate from duplication or retrotransposition events and generally lack the regulatory elements or intact sequences necessary for expression or function. In summary, RNU6-475P is a non-coding, non-functional snRNA pseudogene and is not considered a therapeutic target, biomarker, or drug target[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 475, pseudogene (RNU6-475P).